Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651 · see citing works

Reduced incretin effect in Type 2 (non-insulin dependent) diabetes

Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · see citing works

Quantitative RT-PCR: Pitfalls and Potential

Freeman, W. M., Walker, S. J., & Vrana, K. E. (1999) · BioTechniques · doi:10.2144/99261rv01 · Cited by 1,149 · see citing works

The Glucagon-Like Peptides

Kieffer, T. J., & Habener, J. F. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,056 · see citing works

Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line.

Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903 · see citing works

Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses

NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · see citing works

Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans

Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R. A., & Schmiegel, W. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 822 · see citing works

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor gene

Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · see citing works

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients

T., V., T., K., S., M., & J., H. (2002) · Diabetologia · doi:10.1007/s00125-002-0878-6 · Cited by 518 · see citing works

Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

Willms, B., Werner, J., Holst, J. J., Orskov, C., Creutzfeldt, W., & Nauck, M. A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550773 · Cited by 502 · see citing works

Glucose intolerance caused by a defect in the entero-insular axis: A study in gastric inhibitory polypeptide receptor knockout mice

Miyawaki, K., Yamada, Y., Yano, H., Niwa, H., Ban, N., Ihara, Y., Kubota, A., Fujimoto, S., Kajikawa, M., Kuroe, A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14843 · Cited by 454 · see citing works

Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine.

Ørskov, C., Jeppesen, J., Madsbad, S., & Holst, J. J. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115012 · Cited by 378 · see citing works

Entero-Insular Axis

Unger, R. H. (1969) · Archives of Internal Medicine · doi:10.1001/archinte.1969.00300130043007 · Cited by 371 · see citing works

Glucagonostatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide I(7–36) amide in type I diabetic patients

Creutzfeldt, W., Kleine, N., Willms, B., Ørskov, C., Holst, J. J., & Nauck, M. A. (1996) · Diabetes Care · doi:10.2337/diacare.19.6.580 · Cited by 328 · see citing works

Expression and Functional Activity of Glucagon, Glucagon-Like Peptide I, and Glucose-Dependent Insulinotropic Peptide Receptors in Rat Pancreatic Islet Cells

Moens, K., Heimberg, H., Flamez, D., Huypens, P., Quartier, E., Ling, Z., Pipeleers, D., Gremlich, S., Thorens, B., & Schuit, F. (1996) · Diabetes · doi:10.2337/diab.45.2.257 · Cited by 250 · see citing works

Glucose-Dependent Insulinotropic Polypeptide Is a Growth Factor for β (INS-1) Cells by Pleiotropic Signaling

Trümper, A., Trümper, K., Trusheim, H., Arnold, R., Göke, B., & Hörsch, D. (2001) · Molecular Endocrinology · doi:10.1210/mend.15.9.0688 · Cited by 238 · see citing works

Long-Term Treatment With the Dipeptidyl Peptidase IV Inhibitor P32/98 Causes Sustained Improvements in Glucose Tolerance, Insulin Sensitivity, Hyperinsulinemia, and β-Cell Glucose Responsiveness in VDF (fa/fa) Zucker Rats

Pospisilik, J. A., Stafford, S. G., Demuth, H.-U., Brownsey, R. W., Parkhouse, W. S., Finegood, D. T., McIntosh, C. H. S., & Pederson, R. A. (2002) · Diabetes · doi:10.2337/diabetes.51.4.943 · Cited by 232 · see citing works

Defective Glucose-Dependent Insulinotropic Polypeptide Receptor Expression in Diabetic Fatty Zucker Rats

Lynn, F. C., Pamir, N., Ng, E. H. C., McIntosh, C. H. S., Kieffer, T. J., & Pederson, R. A. (2001) · Diabetes · doi:10.2337/diabetes.50.5.1004 · Cited by 208 · see citing works

Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells

Trümper, A., Trümper, K., & Hörsch, D. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1740233 · Cited by 193 · see citing works

Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice.

Pederson, R. A., Satkunarajah, M., McIntosh, C. H. S., Scrocchi, L. A., Flamez, D., Schuit, F. C., Drucker, D. J., & Wheeler, M. B. (1998) · Diabetes · doi:10.2337/diabetes.47.7.1046 · Cited by 167 · see citing works

Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)—evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins

Vaag, A. A., Holst, J. J., Vølund, A., & Beck‐Nielsen, H. (1996) · European Journal of Endocrinology · doi:10.1530/eje.0.1350425 · Cited by 154 · see citing works

Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat.

Tseng, C., Kieffer, T. J., Jarboe, L. A., Usdin, T. B., & Wolfe, M. M. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119060 · Cited by 149 · see citing works

Glucose-dependent Insulinotropic Polypeptide Activates the Raf-Mek1/2-ERK1/2 Module via a Cyclic AMP/cAMP-dependent Protein Kinase/Rap1-mediated Pathway

Ehses, J. A., Pelech, S., Pederson, R. A., & McIntosh, C. H. S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205055200 · Cited by 133 · see citing works

Functional expression of the rat pancreatic islet glucose-dependent insulinotropic polypeptide receptor: ligand binding and intracellular signaling properties.

Wheeler, M. B., Gelling, R. W., McIntosh, C. H., Georgiou, J., Brown, J. C., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.10.7664683 · Cited by 130 · see citing works

Effect of porcine gastric inhibitory polypeptide on β-cell function in type I and type II diabetes mellitus

Krarup, T., Saurbrey, N., Moody, A. J., Kühl, C., & Madsbad, S. (1987) · Metabolism · doi:10.1016/0026-0495(87)90153-3 · Cited by 128 · see citing works

Preservation of incretin activity after removal of gastric inhibitory polypeptide (GIP) from rat gut extracts by immunoadsorption

Ebert, R., Unger, H., & Creutzfeldt, W. (1983) · Diabetologia · doi:10.1007/bf00257346 · Cited by 120 · see citing works

Enteral Enhancement of Glucose Disposition by Both Insulin-Dependent and Insulin-Independent Processes: A Physiological Role of Glucagon-Like Peptide I

D’Alessio, D. A., Prigeon, R. L., & Ensinck, J. W. (1995) · Diabetes · doi:10.2337/diab.44.12.1433 · Cited by 120 · see citing works

Impaired β-Cell Function, Incretin Effect, and Glucagon Suppression in Patients With Type 1 Diabetes Who Have Normal Fasting Glucose

Greenbaum, C. J., Prigeon, R. L., & D’Alessio, D. A. (2002) · Diabetes · doi:10.2337/diabetes.51.4.951 · Cited by 118 · see citing works

Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs.

Sandhu, H., Wiesenthal, S. R., MacDonald, P. E., McCall, R. H., Tchipashvili, V., Rashid, S., Satkunarajah, M., Irwin, D. M., Shi, Z. Q., BRUBAKER, P. L., et al. (1999) · Diabetes · doi:10.2337/diabetes.48.5.1045 · Cited by 113 · see citing works

The pathogenesis of NIDDM involves a defective expression of the GIP receptor

Holst, J. J., Gromada, J., & Nauck, M. A. (1997) · Diabetologia · doi:10.1007/s001250050779 · Cited by 111 · see citing works

Release of Gastric Inhibitory Polypeptide (GIP) by Intraduodenal Acidification in Rats and Humans and Abolishment of the Incretin Effect of Acid by GIP-Antiserum in Rats

Ebert, R., Illmer, K., & Creutzfeldt, W. (1979) · Gastroenterology · doi:10.1016/s0016-5085(79)80219-x · Cited by 107 · see citing works

Effect of GIP and GLP-1 antagonists on insulin release in the rat

Tseng, C.-C., Zhang, X.-Y., & Wolfe, M. M. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.276.6.e1049 · Cited by 95 · see citing works

Influence of Gastric Inhibitory Polypeptide Antiserum on Glucose-Induced Insulin Secretion in Rats

Ebert, R., & Creutzfeldt, W. (1982) · Endocrinology · doi:10.1210/endo-111-5-1601 · Cited by 93 · see citing works

Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice

Ling, Z., Wu, D., Zambre, Y., Flamez, D., Drucker, D. J., PIPELEERS, D. G., & Schuit, F. C. (2001) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s004280000374 · Cited by 91 · see citing works

Glucose-Dependent Insulinotropic Polypeptide Confers Early Phase Insulin Release to Oral Glucose in Rats: Demonstration by a Receptor Antagonist1

Lewis, J. T., Dayanandan, B., Habener, J. F., & Kieffer, T. J. (2000) · Endocrinology · doi:10.1210/endo.141.10.7750 · Cited by 85 · see citing works

Glucagon-Like Peptide-1, But Not Glucose-Dependent Insulinotropic Peptide, Regulates Fasting Glycemia and Nonenteral Glucose Clearance in Mice

Baggio, L. L., Kieffer, T. J., & Drucker, D. J. (2000) · Endocrinology · doi:10.1210/endo.141.10.7720 · Cited by 79 · see citing works

The Incretin Notion and its Relevance to Diabetes

Habener, J. F. (1993) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30135-x · Cited by 76 · see citing works

Glucagon-like Peptide-1, A Gastrointestinal Hormone with a Pharmaceutical Potential

Holst, J. J. (1999) · Current Medicinal Chemistry · doi:10.2174/092986730611220401163238 · Cited by 75 · see citing works

A New Pathway for Glucose-dependent Insulinotropic Polypeptide (GIP) Receptor Signaling

Ehses, J. A., Lee, S. S. T., Pederson, R. A., & McIntosh, C. H. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103023200 · Cited by 61 · see citing works

Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice

Åhrén, B., & Pacini, G. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.277.6.e996 · Cited by 59 · see citing works

The Insulinotropic Action of Gastric Inhibitory Polypeptide

Pederson, R. A., Schubert, H., & Brown, J. C. (1975) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y75-032 · Cited by 56 · see citing works

Clinical aspects of islet B‐cell function in non‐insulin‐dependent diabetes mellitus

Ward, W. K., Beard, J. C., & Porte, D. (1986) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610020305 · Cited by 51 · see citing works

Antidiabetogenic action of glucagon‐like peptide‐1 related to administration relative to meal intake in subjects with type 2 diabetes

Gutniak, M., Svartberg, J. B., Hellström, P. M., Holst, J. J., Adner, N., & Åhrén, B. (2001) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2001.00862.x · Cited by 27 · see citing works

GIP receptors and signal‐transduction mechanisms

McIntosh, C. H. S., Wheeler, M. B., Gelling, R. W., Brown, J. C., & Pederson, R. A. (1996) · Acta Physiologica Scandinavica · doi:10.1046/j.1365-201x.1996.44267000.x · Cited by 26 · see citing works

Regulation of Islet Hormone Gene Expression by Incretin Hormones

Fehmann, H. C., Gherzi, R., & Göke, B. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1211395 · Cited by 14 · see citing works

Elevated Plasma Levels of Glucagon-Like Peptide-1 After Oral Glucose Ingestion in Patients With Pancreatic Diabetes

HIROYOSHI, M., Tateishi, K., Yasunami, Y., Maeshiro, K., Ono, J., Matsuoka, Y., & Ikeda, S. (1999) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(99)00098-2 · Cited by 10 · see citing works

Glucagon-Like Peptide-1: An Insulinotropic Hormone With Potent Growth Factor Actions at the Pancreatic Islets of Langerhans

Holz, G. G., & Leech, C. A. (2001) · Endocrine updates · doi:10.1007/978-1-4615-1669-9_7 · Cited by 6 · see citing works

Pancreatic regulation of glucose homeostasis.

Röder, P. V., Wu, B., Liu, Y., & Han, W. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.6 · Cited by 985 · see citing works

Glucagon-like peptide-1 receptor: mechanisms and advances in therapy

Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036 · see citing works

The role of incretins in glucose homeostasis and diabetes treatment

Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824 · see citing works

Minireview: Glucagon-Like Peptides Regulate Cell Proliferation and Apoptosis in the Pancreas, Gut, and Central Nervous System

Brubaker, P. L., & Drucker, D. J. (2004) · Endocrinology · doi:10.1210/en.2004-0015 · Cited by 539 · see citing works

Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction

Nauck, M. A., & D‘Alessio, D. A. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01604-7 · Cited by 407 · see citing works

Double Incretin Receptor Knockout (DIRKO) Mice Reveal an Essential Role for the Enteroinsular Axis in Transducing the Glucoregulatory Actions of DPP-IV Inhibitors

Hansotia, T., Baggio, L. L., Delmeire, D., Hinke, S. A., Yamada, Y., Tsukiyama, K., Seino, Y., Holst, J. J., Schuit, F., & Drucker, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1326 · Cited by 309 · see citing works

A Role for β-Cell-Expressed G Protein-Coupled Receptor 119 in Glycemic Control by Enhancing Glucose-Dependent Insulin Release

Chu, Z., Jones, R. M., He, H., Carroll, C., Gutierrez, V., Lucman, A., Moloney, M. K., Gao, H., Mondala, H., Bagnol, D., et al. (2007) · Endocrinology · doi:10.1210/en.2006-1608 · Cited by 295 · see citing works

Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure

Hansotia, T., Maida, A., Flock, G., Yamada, Y., Tsukiyama, K., Seino, Y., & Drucker, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci25483 · Cited by 290 · see citing works

Glucagon-like peptide 1(GLP-1) in biology and pathology

Meier, J. J., & Nauck, M. A. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.538 · Cited by 288 · see citing works

Molecular regulation of pancreatic β-cell mass development, maintenance, and expansion

Ackermann, A. M., & Gannon, M. (2007) · Journal of Molecular Endocrinology · doi:10.1677/jme-06-0053 · Cited by 262 · see citing works

Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors

Preitner, F., Ibberson, M. R., Franklin, I., Binnert, C., Pende, M., Gjinovci, A., Hansotia, T., Drucker, D. J., Wollheim, C. B., Burcelin, R., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci20518 · Cited by 254 · see citing works

Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors

Verspohl, E. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.002 · Cited by 193 · see citing works

GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice

Hansotia, T., & Drucker, D. J. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.07.019 · Cited by 182 · see citing works

Reappraisal of GIP Pharmacology for Metabolic Diseases

Finan, B., Müller, T. D., Clemmensen, C., Perez-Tilve, D., DiMarchi, R. D., & Tschöp, M. H. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.03.005 · Cited by 180 · see citing works

Targeted Ablation of Glucose-dependent Insulinotropic Polypeptide-producing Cells in Transgenic Mice Reduces Obesity and Insulin Resistance Induced by a High Fat Diet

Althage, M. C., Ford, E. L., Wang, S., Tso, P., Polonsky, K. S., & Wice, B. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m710466200 · Cited by 180 · see citing works

Glucose Intolerance and Reduced Proliferation of Pancreatic β-Cells in Transgenic Pigs With Impaired Glucose-Dependent Insulinotropic Polypeptide Function

Renner, S., Fehlings, C., Herbach, N., Hofmann, A., von Waldthausen, D. C., Keßler, B., Ulrichs, K. F. A., Chodnevskaja, I., Moskalenko, V., Amselgruber, W. M., et al. (2010) · Diabetes · doi:10.2337/db09-0519 · Cited by 172 · see citing works

Chemical Ablation of Gastric Inhibitory Polypeptide Receptor Action by Daily (Pro3)GIP Administration Improves Glucose Tolerance and Ameliorates Insulin Resistance and Abnormalities of Islet Structure in Obesity-Related Diabetes

Gault, V. A., Irwin, N., Green, B. D., McCluskey, J. T., Greer, B., Bailey, C. J., Harriott, P., O'Harte, F. P. M., & Flatt, P. R. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2436 · Cited by 172 · see citing works

Chapter 15 Glucose‐Dependent Insulinotropic Polypeptide (Gastric Inhibitory Polypeptide; GIP)

McIntosh, C. H. S., Widenmaier, S. B., & Kim, S. (2009) · Vitamins and hormones · doi:10.1016/s0083-6729(08)00615-8 · Cited by 172 · see citing works

Glucose-Dependent Insulinotropic Polypeptide Promotes β-(INS-1) Cell Survival via Cyclic Adenosine Monophosphate-Mediated Caspase-3 Inhibition and Regulation of p38 Mitogen-Activated Protein Kinase

Ehses, J. A., Casilla, V. R., Doty, T., Pospisilik, J. A., Winter, K. D., Demuth, H., Pederson, R. A., & McIntosh, C. H. S. (2003) · Endocrinology · doi:10.1210/en.2002-0068 · Cited by 159 · see citing works

Glucose-Dependent Insulinotropic Polypeptide Is Expressed in Pancreatic Islet α-Cells and Promotes Insulin Secretion

Fujita, Y., Wideman, R. D., Asadi, A., Yang, G. K., Baker, R. K., Webber, T. D., Zhang, T., Wang, R., Ao, Z., Warnock, G. L., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.049 · Cited by 152 · see citing works

Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice

Knerr, P. J., Mowery, S. A., Douros, J. D., Premdjee, B., Hjøllund, K. R., He, Y., Kruse Hansen, A. M., Olsen, A. K., Perez-Tilve, D., DiMarchi, R. D., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101533 · Cited by 147 · see citing works

Dominant-Negative Effects of a Novel Mutated Ins2 Allele Causes Early-Onset Diabetes and Severe β-Cell Loss in Munich Ins2C95S Mutant Mice

Herbach, N., Rathkolb, B., Kemter, E., Pichl, L., Klaften, M., de Angelis, M. H., Halban, P. A., Wolf, E., Aigner, B., & Wanke, R. (2007) · Diabetes · doi:10.2337/db06-0658 · Cited by 147 · see citing works

TCF1 links GIPR signaling to the control of beta cell function and survival

Campbell, J. E., Ussher, J. R., Mulvihill, E. E., Kolic, J., Baggio, L. L., Cao, X., Liu, Y., Lamont, B. J., Morii, T., Streutker, C. J., et al. (2016) · Nature Medicine · doi:10.1038/nm.3997 · Cited by 142 · see citing works

Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms

Campbell, J. E. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101139 · Cited by 133 · see citing works

Xenografted Islet Cell Clusters From INSLEA29Y Transgenic Pigs Rescue Diabetes and Prevent Immune Rejection in Humanized Mice

Klymiuk, N., Buerck, L. W., Bähr, A., Offers, M., Keßler, B., Wuensch, A., Kurome, M., Thormann, M., Lochner, K., Nagashima, H., et al. (2012) · Diabetes · doi:10.2337/db11-1325 · Cited by 133 · see citing works

Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications

Irwin, N., & Flatt, P. R. (2009) · Diabetologia · doi:10.1007/s00125-009-1422-8 · Cited by 125 · see citing works

The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets

El, K., Douros, J. D., Willard, F. S., Novikoff, A., Sargsyan, A., Perez-Tilve, D., Wainscott, D. B., Yang, B., Chen, A., Wothe, D., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00811-0 · Cited by 118 · see citing works

Targeting β-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins

Salehi, M., Aulinger, B. A., & D’Alessio, D. A. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0031 · Cited by 106 · see citing works

Nutrient-Induced Cellular Mechanisms of Gut Hormone Secretion

Lu, V. B., Gribble, F. M., & Reimann, F. M. (2021) · Nutrients · doi:10.3390/nu13030883 · Cited by 105 · see citing works

Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non‐alcoholic fatty liver disease

Zarrinpar, A., & Loomba, R. S. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12084 · Cited by 102 · see citing works

Glucose-dependent insulinotropic polypeptide receptor therapies for the treatment of obesity, do agonists=antagonists?

Killion, E. A., Lu, S.-C., Fort, M., Yamada, Y., Véniant, M. M., & Lloyd, D. J. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz002 · Cited by 94 · see citing works

Glucose-dependent insulinotropic polypeptide (GIP)

Müller, T. D., Adriaenssens, A. E., Ahrén, B., Blüher, M., Birkenfeld, A. L., Campbell, J. E., Coghlan, M. P., D’Alessio, D. D., Deacon, C. F., DelPrato, S., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102118 · Cited by 99 · see citing works

K-cells and Glucose-Dependent Insulinotropic Polypeptide in Health and Disease

Cho, Y. M., & Kieffer, T. J. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00004-7 · Cited by 93 · see citing works

GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys

Lu, S.-C., Chen, M., Atangan, L., Killion, E. A., Komorowski, R., Cheng, Y., Netirojjanakul, C., Falsey, J. R., Stolina, M., Dwyer, D., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100263 · Cited by 91 · see citing works

Effects of Sitagliptin and Metformin Treatment on Incretin Hormone and Insulin Secretory Responses to Oral and “Isoglycemic” Intravenous Glucose

Vardarli, I., Arndt, E., Deacon, C. F., Holst, J. J., & Nauck, M. A. (2013) · Diabetes · doi:10.2337/db13-0805 · Cited by 90 · see citing works

Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents

Gasbjerg, L. S., Gabe, M. B. N., Hartmann, B., Christensen, M. B., Knop, F. K., Holst, J. J., & Rosenkilde, M. M. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.021 · Cited by 85 · see citing works

Differential Importance of Glucose-Dependent Insulinotropic Polypeptide vs Glucagon-Like Peptide 1 Receptor Signaling for Beta Cell Survival in Mice

Maida, A., Hansotia, T., Longuet, C., Seino, Y., & Drucker, D. J. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.09.004 · Cited by 85 · see citing works

GPR119 Regulates Murine Glucose Homeostasis Through Incretin Receptor-Dependent and Independent Mechanisms

Flock, G. B., Holland, D. P., Seino, Y., & Drucker, D. J. (2010) · Endocrinology · doi:10.1210/en.2010-1047 · Cited by 84 · see citing works

The Role of G Protein–Coupled Receptors and Receptor Kinases in Pancreatic β-Cell Function and Diabetes

Varney, M. J., & Benovic, J. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001015 · Cited by 83 · see citing works

Glucose-dependent insulinotropic polypeptide receptor deficiency leads to modifications of trabecular bone volume and quality in mice

Gaudin-Audrain, C., Irwin, N., Mansur, S. A., Flatt, P. R., Thorens, B., Baslé, M. F., Chappard, D., & Mabilleau, G. (2012) · Bone · doi:10.1016/j.bone.2012.11.039 · Cited by 80 · see citing works

Functional Consequences of Glucagon-like Peptide-1 Receptor Cross-talk and Trafficking

Roed, S. N., Nøhr, A. C., Wismann, P., Iversen, H. K., Bräuner‐Osborne, H., Knudsen, S. M., & Waldhoer, M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.592436 · Cited by 78 · see citing works

Xenin-25 Potentiates Glucose-dependent Insulinotropic Polypeptide Action via a Novel Cholinergic Relay Mechanism

Wice, B. M., Wang, S., Crimmins, D. L., Diggs‐Andrews, K. A., Althage, M. C., Ford, E. L., Tran, H. D., Ohlendorf, M. F., Griest, T. A., Wang, Q., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.129304 · Cited by 74 · see citing works

Glucose-Dependent Insulinotropic Peptide Stimulates Glucagon-Like Peptide 1 Production by Pancreatic Islets via Interleukin 6, Produced by α Cells

Timper, K., Dalmas, É., Dror, E., Rütti, S., Thienel, C., Sauter, N. S., Bouzakri, K., Bédat, B., Pattou, F. N., Kerr-Conte, J. A., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.03.003 · Cited by 73 · see citing works

Effects of acute and chronic administration of GIP analogues on cognition, synaptic plasticity and neurogenesis in mice

Faivre, É., Hamilton, A., & Hölscher, C. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.11.007 · Cited by 70 · see citing works

Pharmacological antagonism of the incretin system protects against diet-induced obesity

Svendsen, B., Capozzi, M. E., Nui, J., Hannou, S. A., Finan, B., Naylor, J., Ravn, P., D'Alessio, D. A., & Campbell, J. E. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2019.11.018 · Cited by 67 · see citing works

Mango Supplementation Modulates Gut Microbial Dysbiosis and Short-Chain Fatty Acid Production Independent of Body Weight Reduction in C57BL/6 Mice Fed a High-Fat Diet

Ojo, B. A., El-Rassi, G. D., Payton, M. E., Perkins-Veazie, P. M., Clarke, S. L., Smith, B. J., & Lucas, E. A. (2016) · Journal of Nutrition · doi:10.3945/jn.115.226688 · Cited by 65 · see citing works

Functional Analysis of Seven Genes Linked to Body Mass Index and Adiposity by Genome-Wide Association Studies: A Review

Speakman, J. R. (2013) · Human Heredity · doi:10.1159/000353585 · Cited by 61 · see citing works

Overexpression of a dominant negative GIP receptor in transgenic mice results in disturbed postnatal pancreatic islet and beta-cell development

Herbach, N., Göke, B., Schneider, M. R., Hermanns, W., Wolf, E., & Wanke, R. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.08.021 · Cited by 59 · see citing works

Pancreatic and Extrapancreatic Effects of Gastric Inhibitory Polypeptide

Yamada, Y., Miyawaki, K., Tsukiyama, K., Harada, N., Yamada, C., & Seino, Y. (2006) · Diabetes · doi:10.2337/db06-s011 · Cited by 54 · see citing works

Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems

Yang, B., Gelfanov, V. M., El, K., Chen, A., Rohlfs, R., DuBois, B., Kruse Hansen, A. M., Perez-Tilve, D., Knerr, P. J., D'Alessio, D., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101638 · Cited by 55 · see citing works

Incretins, diabetes, and bariatric surgery: a review

Fetner, R., McGinty, J., Russell, C. D., Pi-Sunyer, X., & Laferrère, B. (2005) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2005.09.001 · Cited by 52 · see citing works

Mechanisms to Elevate Endogenous GLP-1 Beyond Injectable GLP-1 Analogs and Metabolic Surgery

Briere, D. A., Bueno, A. B., Gunn, E. J., Michael, M. D., & Sloop, K. W. (2017) · Diabetes · doi:10.2337/db17-0607 · Cited by 51 · see citing works

Transgenic Rescue of Adipocyte Glucose-dependent Insulinotropic Polypeptide Receptor Expression Restores High Fat Diet-induced Body Weight Gain

Ugleholdt, R., Pedersen, J., Bassi, M. R., Füchtbauer, E., Jørgensen, S. M., Kissow, H., Nytofte, N., Poulsen, S. S., ROSENKILDE, M. M., Seino, Y., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.311779 · Cited by 49 · see citing works

Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice

Irwin, N., Gault, V. A., Green, B. D., Greer, B., McCluskey, J. T., Harriott, P., O'Harte, F. P. M., & Flatt, P. R. (2004) · Biological Chemistry · doi:10.1515/bc.2004.110 · Cited by 49 · see citing works

Double incretin receptor knock-out (DIRKO) mice present with alterations of trabecular and cortical micromorphology and bone strength

Mieczkowska, A., Mansur, S., Bouvard, B., Flatt, P. R., Thorens, B., Irwin, N., Chappard, D., & Mabilleau, G. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2845-8 · Cited by 47 · see citing works

Functional interrogation of twenty type 2 diabetes-associated genes using isogenic human embryonic stem cell-derived β-like cells

Xue, D., Narisu, N., Taylor, D. L., Zhang, M., Grenko, C. M., Taylor, H. J., Yan, T., Tang, X., Sinha, N., Zhu, J., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.09.013 · Cited by 46 · see citing works

Active immunisation against gastric inhibitory polypeptide (GIP) improves blood glucose control in an animal model of obesity-diabetes

Irwin, N., McClean, P. L., Patterson, S., Hunter, K., & Flatt, P. R. (2008) · Biological Chemistry · doi:10.1515/bc.2009.002 · Cited by 41 · see citing works

Pleiotropic Actions of the Incretin Hormones

McIntosh, C. H. S., Widenmaier, S. B., & Kim, S. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00002-3 · Cited by 40 · see citing works

Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus

Holst, J. J., & McGill, M. A. (2011) · Clinical Drug Investigation · doi:10.2165/11595370-000000000-00000 · Cited by 40 · see citing works

Gastric inhibitory polypeptide receptor antagonist, SKL‐14959, suppressed body weight gain on diet‐induced obesity mice

Nakamura, T., Tanimoto, H., Mizuno, Y., Okamoto, M., Takeuchi, M., Tsubamoto, Y., & Noda, H. (2018) · Obesity Science & Practice · doi:10.1002/osp4.164 · Cited by 38 · see citing works

Development and characterisation of a novel glucagon like peptide-1 receptor antibody

Biggs, E. K., Liang, L., Naylor, J., Madalli, S., Collier, R., Coghlan, M. P., Baker, D. J., Hornigold, D. C., Ravn, P., Reimann, F. M., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4491-0 · Cited by 37 · see citing works

Effects of Incretin-Related Diabetes Drugs on Bone Formation and Bone Resorption

Kitaura, H., Ogawa, S., Ohori, F., Noguchi, T., Marahleh, A., Nara, Y., Pramusita, A., Kinjo, R., Ma, J., Kanou, K., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126578 · Cited by 40 · see citing works

Postnatal Development of Numbers and Mean Sizes of Pancreatic Islets and Beta-Cells in Healthy Mice and GIPRdn Transgenic Diabetic Mice

Herbach, N., Bergmayr, M., Göke, B., Wolf, E., & Wanke, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022814 · Cited by 36 · see citing works

Effects of gastric inhibitory polypeptide, glucagon‐like peptide‐1 and glucagon‐like peptide‐1 receptor agonists on Bone Cell Metabolism

Hansen, M. S., Tencerová, M., Frølich, J. S., Kassem, M. S., & Frost, M. (2017) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12850 · Cited by 36 · see citing works

Insulin Action in the Double Incretin Receptor Knockout Mouse

Ayala, J. E., Bracy, D. P., Hansotia, T., Flock, G. B., Seino, Y., Wasserman, D. H., & Drucker, D. J. (2007) · Diabetes · doi:10.2337/db07-0704 · Cited by 36 · see citing works

DPP-4 inhibition contributes to the prevention of hypoglycaemia through a GIP–glucagon counterregulatory axis in mice

Malmgren, S., & Åhrén, B. (2015) · Diabetologia · doi:10.1007/s00125-015-3518-7 · Cited by 34 · see citing works

Incretin actions and consequences of incretin‐based therapies: lessons from complementary animal models

Renner, S., Blutke, A., Streckel, E., Wanke, R., & Wolf, E. (2015) · The Journal of Pathology · doi:10.1002/path.4655 · Cited by 31 · see citing works

Blockade of gastric inhibitory polypeptide (GIP) action as a novel means of countering insulin resistance in the treatment of obesity-diabetes

Irwin, N., Gault, V. A., O’Harte, F. P. M., & Flatt, P. R. (2020) · Peptides · doi:10.1016/j.peptides.2019.170203 · Cited by 27 · see citing works

Pancreatic glucose-dependent insulinotropic polypeptide (GIP) (1–30) expression is upregulated in diabetes and PEGylated GIP(1–30) can suppress the progression of low-dose-STZ-induced hyperglycaemia in mice

Yanagimachi, T., Fujita, Y., Takeda, Y., Honjo, J., Atageldiyeva, K. K., Takiyama, Y., Abiko, A., Makino, Y., Kieffer, T. J., & Haneda, M. (2015) · Diabetologia · doi:10.1007/s00125-015-3842-y · Cited by 27 · see citing works

Glucagon and insulin secretion, insulin clearance, and fasting glucose in GIP receptor and GLP-1 receptor knockout mice

Tura, A., Pacini, G., Yamada, Y., Seino, Y., & Åhrén, B. (2018) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00288.2018 · Cited by 24 · see citing works

Investigating GIPR (Ant)Agonism: A Structural Analysis of GIP and Its Receptor

Smit, F. X., van der Velden, W. J. C., Kizilkaya, H. S., Nørskov, A., Lückmann, M., Hansen, T. N., Sparre‐Ulrich, A. H., Qvortrup, K. M., Frimurer, T. M., & ROSENKILDE, M. M. (2020) · Structure · doi:10.1016/j.str.2021.04.001 · Cited by 24 · see citing works

The GLP-1R as a model for understanding and exploiting biased agonism in next-generation medicines

Douros, J. D., Mokrosiński, J., & Finan, B. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0226 · Cited by 23 · see citing works

Functional GIP receptors play a major role in islet compensatory response to high fat feeding in mice

Moffett, R. C., Vasu, S., & Flatt, P. R. (2015) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2015.02.006 · Cited by 22 · see citing works

Type 2 diabetes increases oocyte mtDNA mutations which are eliminated in the offspring by bottleneck effect

Li, L., Wu, C.-S., Hou, G.-M., Dong, M., Wang, Z., Hou, Y., Schatten, H., Zhang, G., & Sun, Q. (2018) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-018-0423-1 · Cited by 21 · see citing works

Daily administration of the GIP‐R antagonist (Pro 3 )GIP in streptozotocin‐induced diabetes suggests that insulin‐dependent mechanisms are critical to anti–obesity‐diabetes actions of (Pro 3 )GIP

McClean, P. L., Gault, V. A., Irwin, N., McCluskey, J. T., & Flatt, P. R. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00712.x · Cited by 20 · see citing works

Incretin-based therapy for the treatment of bone fragility in diabetes mellitus

Mabilleau, G., Gobron, B., Bouvard, B., & Chappard, D. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.008 · Cited by 19 · see citing works

Type 1 diabetes affects zona pellucida and genome methylation in oocytes and granulosa cells

Li, L., Jing, Y., Dong, M., Fan, L., Li, Q., Wang, Z., Hou, Y., Schatten, H., Zhang, C., & Sun, Q. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110627 · Cited by 18 · see citing works

Chronic peptide-based GIP receptor inhibition exhibits modest glucose metabolic changes in mice when administered either alone or combined with GLP-1 agonism

West, J. A., Tsakmaki, A., Ghosh, S. S., Parkes, D. G., Grønlund, R. V., Pedersen, P. J., MAGGS, D. G., Rajagopalan, H., & Bewick, G. A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249239 · Cited by 16 · see citing works

The Insulin Response to Oral Glucose in GIP and GLP-1 Receptor Knockout Mice: Review of the Literature and Stepwise Glucose Dose Response Studies in Female Mice

Ahrén, B., Yamada, Y., & Seino, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.665537 · Cited by 15 · see citing works

GLP-1 Receptor Signaling and Oral Dysfunction: A Narrative Review on the Mechanistic Basis of Semaglutide-Related Oral Adverse Effects

Barać, M., & Roganović, J. (2025) · Biology · doi:10.3390/biology14121650 · Cited by 19 · see citing works

GIP: No Longer the Neglected Incretin Twin?

Kulkarni, R. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001027 · Cited by 15 · see citing works

The Expression and Function of Glucose-Dependent Insulinotropic Polypeptide in the Embryonic Mouse Pancreas

Prasadan, K. L., Koizumi, M., Tulachan, S., Shiota, C., Lath, N. R., Paredes, J. L., Guo, P., El‐Gohary, Y., Malek, M. M., Shah, S. R., et al. (2011) · Diabetes · doi:10.2337/db09-0035 · Cited by 15 · see citing works

Interplay between bone and incretin hormones: A review

Mabilleau, G. (2016) · Morphologie · doi:10.1016/j.morpho.2016.06.004 · Cited by 15 · see citing works

The Incretins and Pancreatic β-Cells: Use of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide to Cure Type 2 Diabetes Mellitus

Kim, M., & Lee, M. (2010) · Korean Diabetes Journal · doi:10.4093/kdj.2010.34.1.2 · Cited by 14 · see citing works

Increased insulin clearance in mice with double deletion of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors

Tura, A., Bizzotto, R., Yamada, Y., Seino, Y., Pacini, G., & Åhrén, B. (2018) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00181.2017 · Cited by 13 · see citing works

Dual-Monoclonal, Sandwich Immunoassay Specific for Glucose-Dependent Insulinotropic Peptide1-42, the Active Form of the Incretin Hormone

Troutt, J. S., Siegel, R. W., Chen, J., Sloan, J. H., Deeg, M. A., Cao, G., & Konrad, R. J. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.159954 · Cited by 13 · see citing works

The mediation by GLP-1 receptors of glucagon-induced insulin secretion revisited in GLP-1 receptor knockout mice

Ahrén, B., Yamada, Y., & Seino, Y. (2021) · Peptides · doi:10.1016/j.peptides.2020.170434 · Cited by 12 · see citing works

Early insulin therapy prevents beta cell loss in a mouse model for permanent neonatal diabetes (Munich Ins2 C95S)

Kautz, S., van Bürck, L., Schuster, M., Wolf, E., Wanke, R., & Herbach, N. (2011) · Diabetologia · doi:10.1007/s00125-011-2362-7 · Cited by 12 · see citing works

Gastric inhibitory polypeptide is the major insulinotropic factor in K(ATP) null mice

Tsukiyama, K., Yamada, Y., Miyawaki, K., Hamasaki, A., Nagashima, K., Hosokawa, M., Fujimoto, S., Takahashi, A., Toyoda, K., Toyokuni, S., et al. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1510407 · Cited by 11 · see citing works

Gsα-dependent signaling is required for postnatal establishment of a functional β-cell mass

Serra-Navarro, B., Fernandez‐Ruiz, R., García, A., Pradas-Juni, M., Fernández‐Rebollo, E., Esteban, Y., Mir-Coll, J., Mathieu, J., Dalle, S., Hahn, M., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101264 · Cited by 11 · see citing works

Phenotypic and pathomorphological characteristics of a novel mutant mouse model for maturity-onset diabetes of the young type 2 (MODY 2)

van Bürck, L., Blutke, A., Kautz, S., Rathkolb, B., Klaften, M., Wagner, S., Kemter, E., de Angelis, M. H., Wolf, E., Aigner, B., et al. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00465.2009 · Cited by 11 · see citing works

HNF4α is a novel regulator of intestinal glucose-dependent insulinotropic polypeptide

Girard, R., Darsigny, M., Jones, C. M., Maloum-Rami, F., Gélinas, Y., Carpentier, A. C., Laplante, M., Perreault, N., & Boudreau, F. (2019) · Scientific Reports · doi:10.1038/s41598-019-41061-z · Cited by 10 · see citing works

Incretin hormone receptors are required for normal beta cell development and function in female mice

Omar, B. A., Ahlkvist, L., Yamada, Y., Seino, Y., & Åhrén, B. (2016) · Peptides · doi:10.1016/j.peptides.2016.03.012 · Cited by 9 · see citing works

Pancreatic β-cell remodeling in health and aging: Lessons from rodents and humans

Darwish, R., Alcibahy, Y., Dhawan, S., Butler, A. E., & Moin, A. S. M. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102815 · Cited by 11 · see citing works

The role of apolipoprotein A-IV in regulating glucagon-like peptide-1 secretion

Wang, F., Yang, Q., Huesman, S., Xu, M., Li, X., Lou, D., Woods, S. C., Marziano, C., & Tso, P. (2015) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00075.2015 · Cited by 9 · see citing works

Diets influence the diabetic phenotype of transgenic mice expressing a dominant negative glucose-dependent insulinotropic polypeptide receptor (GIPRdn)

Herbach, N., Göke, B., Wolf, E., & Wanke, R. (2007) · Regulatory Peptides · doi:10.1016/j.regpep.2007.10.005 · Cited by 9 · see citing works

Molecular Characterization of Grass Carp GIPR and Effect of Nutrition States, Insulin, and Glucagon on Its Expression

Yang, G., Liang, X., Jiang, Y., Li, C., Zhang, Y., Zhang, X., Chang, X., Shen, Y., & Meng, X. (2022) · Aquaculture Nutrition · doi:10.1155/2022/4330251 · Cited by 7 · see citing works

Does glucose-dependent insulinotropic polypeptide receptor blockade as well as agonism have a role to play in management of obesity and diabetes?

Lafferty, R. A., Flatt, P. R., Gault, V. A., & Irwin, N. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0339 · Cited by 7 · see citing works

GIPR gene expression in testis is mouse specific and can impact male mouse fertility

Killion, E. A., Hussien, R., Shkumatov, A. A., Davies, R., Lloyd, D. J., Véniant, M. M., Lebrec, H. N., & Fort, M. M. (2022) · Andrology · doi:10.1111/andr.13166 · Cited by 6 · see citing works

Islet adaptation in GIP receptor knockout mice

Åhrén, B., Yamada, Y., & Seino, Y. (2019) · Peptides · doi:10.1016/j.peptides.2019.170152 · Cited by 6 · see citing works

The enteroinsular axis in glucose dependent insulinotropic polypeptide receptor knockout (GIPR-/-) miee

Pamir, N. (2009) · cIRcle (University of British Columbia) · doi:10.14288/1.0099678

Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice.

Pederson, R. A., Satkunarajah, M., McIntosh, C. H. S., Scrocchi, L. A., Flamez, D., Schuit, F. C., Drucker, D. J., & Wheeler, M. B. (1998) · Diabetes · doi:10.2337/diabetes.47.7.1046 · Cited by 167 · see citing works

Glucose intolerance caused by a defect in the entero-insular axis: A study in gastric inhibitory polypeptide receptor knockout mice

Miyawaki, K., Yamada, Y., Yano, H., Niwa, H., Ban, N., Ihara, Y., Kubota, A., Fujimoto, S., Kajikawa, M., Kuroe, A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14843 · Cited by 454 · see citing works

Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis

Ali, S., Lamont, B. J., Charron, M. J., & Drucker, D. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43615 · Cited by 109 · see citing works

SAT037 Glucagon-like Peptide-1 Receptor Knockout Mice Do Not Compensate For The Lack Of Incretin Action By Increasing Glucose-dependent Insulinotropic Polypeptide Secretion

Galsgaard, K. D., Kissow, H., Smits, M. M., & Juul, J. J. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad114.905 · Cited by 1 · see citing works